Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Eribulin Stories

2012-07-17 12:20:03

- Partnership Based on Open Innovation That Leverages Eisai's Natural Product Chemistry-Based Drug Discovery Platform -Tokyo, July 17, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a research collaboration with U.S. biopharmaceutical company Verastem, Inc. for the generation of small molecule Wnt inhibitors that target cancer stem cells. Based on this agreement, Eisai will synthesize analogs of VS-507 (salinomycin) with the aim of...

2012-07-09 14:23:20

WOODCLIFF LAKE, N.J., July 9, 2012 /PRNewswire/ -- Eisai Inc. today announced preliminary results from a recently completed phase III study of Halaven versus capecitabine (Xeloda®) in women with locally advanced or metastatic breast cancer. The trial did not meet the pre-specified criteria for either of the co-primary endpoints of overall survival (OS) and progression-free survival (PFS). The study did show, however, a trend toward improved OS for patients who received Halaven compared...

2012-04-24 02:29:04

New Treatment Option Significantly Prolongs Overall Survival in Pre-treated Metastatic Breast Cancer Patients MISSISSAUGA, ON, April 24, 2012 /PRNewswire/ - Eisai Limited, a wholly-owned Canadian subsidiary of Eisai Inc., announced today the launch of Halaven(TM) (eribulin mesylate), the latest treatment approved by Health Canada for metastatic breast cancer.  Halaven(TM) is indicated for the treatment of patients with metastatic breast cancer who have previously received at...

2012-04-23 20:20:12

Tokyo, Apr 23, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that the German Federal Joint Committee (G-BA)(1), the supreme decision-making body for the self-governing medical system in Germany, considers the use of Halaven(R) (eribulin mesylate) to have additional benefit versus comparative treatments, defined by the G-BA for women who have already had extensive prior treatment for metastatic or locally advanced breast cancer.This assessment by the G-BA affirms the additional...

2011-12-15 00:20:01

Tokyo, Dec 15, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited (Eisai Canada) has received approval from Health Canada for Halaven (eribulin mesylate), a novel anticancer agent discovered and developed by Eisai, for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an...

2011-07-19 12:35:02

Tokyo, July 19, 2011 - (JCN Newswire) - Eisai Co., Ltd. today announced the launch of its novel anticancer agent Halaven(R) in Japan for the treatment of inoperable or recurrent breast cancer. Halaven(R) is the first novel anticancer agent to be discovered and developed by the Eisai. Having simultaneously submitted marketing authorization applications to the regulatory authorities in Japan, the United States and the European Union (EU) in March 2010, the company first launched Halaven(R) in...

2011-04-22 04:35:01

Tokyo, Apr 22, 2011 - (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) announced today that it has received approval to market its novel anticancer Halaven(R) Injection 1mg (eribulin mesylate) in Japan for the treatment of inoperable and recurrent breast cancer. Discovered and developed by Eisai, Halaven is now approved in each of the world's three largest pharmaceutical markets, comprising Japan, the United States and the European Union (EU).The Japan marketing authorization application for...

2010-03-30 19:04:00

WOODCLIFF LAKE, N.J., March 30 /PRNewswire/ -- Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union (EU). Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. The submissions are based primarily on...

2009-10-30 06:30:00

WOODCLIFF LAKE, N.J., Oct. 30 /PRNewswire/ -- Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer. This global Phase III study, known as "EMBRACE," (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389), was an open-label, randomized, parallel two-arm, multi-center study of 762 women with...